APA (7th ed.) Citation

JC, N., M, B., M, W., A, D., S, P., G, P., . . . M, B. (2025). [18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): A prospective multicentre study. The lancet. Gastroenterology & hepatology, 10(4), 306. https://doi.org/10.1016/S2468-1253(25)00011-1

Chicago Style (17th ed.) Citation

JC, Nault, et al. "[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for Staging Optimisation and Treatment Modification in Hepatocellular Carcinoma (PET-HCC01): A Prospective Multicentre Study." The Lancet. Gastroenterology & Hepatology 10, no. 4 (2025): 306. https://doi.org/10.1016/S2468-1253(25)00011-1.

MLA (9th ed.) Citation

JC, Nault, et al. "[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for Staging Optimisation and Treatment Modification in Hepatocellular Carcinoma (PET-HCC01): A Prospective Multicentre Study." The Lancet. Gastroenterology & Hepatology, vol. 10, no. 4, 2025, p. 306, https://doi.org/10.1016/S2468-1253(25)00011-1.